Contemporary Medical Therapy for Heart Failure Patients with Reduced Ejection Fraction

Abstract This chapter outlines the goals of therapy for the contemporary management of patients with heart failure with reduced ejection fraction (HFrEF). It provides an overview of general measures, including dietary and activity recommendations, and then focuses on diuretic use for symptom management and the foundational therapies to improve clinical outcomes in these patients. Emphasis is given on the rationale and pathophysiologic basis for different therapies and the effects on hemodynamics, ventricular structure, functional status, and clinical outcomes. Furthermore, clinical guidance is provided around side effects, complications, and drug interactions with these different therapies.

• Publication year

  2020

• Venue

  Heart failure

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/B978-0-323-60987-6.00037-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Diuretic Treatment in Heart Failure.

  2018cited by this paper
• Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

  2017cited by this paper
• Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.

  2017cited by this paper
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

  2017cited by this paper
• Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.

  2017cited by this paper
• Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.

  2016cited by this paper
• Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

  2015cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data.

  2014cited by this paper
• Nitrate therapy for heart failure: benefits and strategies to overcome tolerance.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Diuretics and ultrafiltration in acute decompensated heart failure.

  2012cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Diuretic strategies in patients with acute decompensated heart failure.

  2011cited by this paper
• Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compensated Heart Failure With New York Heart Association Class III (Class C) (SMAC-HF Study)

  2011cited by this paper
• Contemporary Reviews in Cardiovascular Medicine Hydralazine and Isosorbide Dinitrate in Heart Failure Historical Perspective, Mechanisms, and Future Directions

  2011cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• Combination of loop diuretics with thiazide-type diuretics in heart failure.

  2010cited by this paper
• Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction

  2010cited by this paper
• Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

  2009cited by this paper
• Loop Diuretics in Acute Decompensated Heart Failure: Necessary? Evil? A Necessary Evil?

  2009cited by this paper
• Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

  2009cited by this paper
• B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode.

  2009cited by this paper
• Sodium Retention in Heart Failure and Cirrhosis: Potential Role of Natriuretic Doses of Mineralocorticoid Antagonist?

  2009cited by this paper
• Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial

  2007cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Mineralocorticoid receptor activation and cardiac fibrosis.

  2007cited by this paper
• Effect of beta‐blocker therapy on functional status in patients with heart failure — A meta‐analysis

  2006cited by this paper
• A method of determining the dose of digoxin for heart failure in the modern era.

  2006cited by this paper
• A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure

  2006cited by this paper
• Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

  2006cited by this paper
• ANG II-induced cardiac molecular and cellular events: role of aldosterone.

  2006cited by this paper
• Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

  2005cited by this paper
• Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction

  2005cited by this paper
• Angiotensin II and Aldosterone Regulate Gene Transcription Via Functional Mineralocortocoid Receptors in Human Coronary Artery Smooth Muscle Cells

  2005cited by this paper
• Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III

  2005cited by this paper
• Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction The Protective Effects of Captopril

  2005cited by this paper
• Explaining the phenomenon of nitrate tolerance.

  2005cited by this paper
• Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction

  2004cited by this paper
• Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study

  2004cited by this paper
• Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• Immediate Administration of Mineralocorticoid Receptor Antagonist Spironolactone Prevents Post-Infarct Left Ventricular Remodeling Associated With Suppression of a Marker of Myocardial Collagen Synthesis in Patients With First Anterior Acute Myocardial Infarction

  2003cited by this paper
• Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

  2003cited by this paper
• Myocardial Contractile Reserve by Dobutamine Stress Echocardiography Predicts Improvement in Ejection Fraction With &bgr;-Blockade in Patients With Heart Failure: The &bgr;-Blocker Evaluation of Survival Trial (BEST)

  2003cited by this paper
• Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

  2003cited by this paper
• Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.

  2003cited by this paper
• Literature alert

  2002cited by this paper
• Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure

  2002cited by this paper
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

  2002cited by this paper
• Effect of carvedilol on survival in severe chronic heart failure.

  2001cited by this paper
• Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

  2001cited by this paper
• A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• β-Adrenergic Receptor Blockade in Chronic Heart Failure

  2000cited by this paper
• Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy.

  2000cited by this paper
• Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

  2000cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

  1999cited by this paper
• Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

  1999cited by this paper
• Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.

  1999cited by this paper
• Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.

  1999cited by this paper
• Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.

  1999cited by this paper
• How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

  1999cited by this paper
• The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

  1999cited by this paper
• Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.

  1999cited by this paper
• Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases.

  1998cited by this paper
• Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease

  1997cited by this paper
• Comparative Effects of Losartan and Enalapril on Exercise Capacity and Clinical Status in Patients With Heart Failure fn1fn1This study was supported by a grant from Merck Research Laboratories, West Point, Pennsylvania.

  1997cited by this paper
• Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction.

  1997cited by this paper
• The effect of digoxin on mortality and morbidity in patients with heart failure.

  1997cited by this paper
• Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease

  1997cited by this paper
• Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat.

  1997cited by this paper
• Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

  1997cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper
• Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

  1996cited by this paper
• Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

  1996cited by this paper
• Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.

  1995cited by this paper
• A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.

  1995cited by this paper
• A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees.

  1994cited by this paper
• Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure

  1993cited by this paper
• Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

  1993cited by this paper
• Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.

  1993cited by this paper
• Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.

  1993cited by this paper
• Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

  1993cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.

  1991cited by this paper

• Improving Quality of Life in Heart Failure

  2021cites this paper